

Product Experience Research Report of GenellI L-Ergothioneine Eye Wash Joint Research by Pharnex & GenellI Biotech

I. Main Background of the Research:

The incidence rate of dry eyes is as high as over 20%, with a large base of patients. Moreover, the number of dry eye patients is increasing at a rate of over 10% per year. The main manifestations of dry eye problems include: eye dryness, eye itching, eye redness, foreign body sensation, photophobia/wind sensitivity with tearing, sticky secretions, blurred vision, a burning and painful sensation, and others. These symptoms have become common issues plaguing the eye health of many people. GeneIII Biotech, in collaboration with Pharnex, launched the public welfare activity of "Looking for 1,000 Dry Eye Experiencers". Through activities at the CMC exhibition mainly, more than 500 users were found to experience the GeneIII L-Ergothioneine Eye Wash for free. A relatively in-depth follow-up survey on 88 users with dry eye were conducted.

II. Core Conclusions of the Report:

I) Nearly 80% of the respondents believe that it has significantly improved their comprehensive symptoms related to dry eyes.

Question 12: After continuously using the product, has there been a significant improvement in your dry eye symptoms? [Single-choice question]

Options	Subtotal	Proportion
Very obvious	20	22.73%
Obvious	50	56.82%
General	12	1 3.64%
Not obvious	4	4.55%
Extremely not obvious	2	■ 2.27%

The number of people filling in this question effectively: 88

II) 85% of the people reported that the effect experience of GeneIII L-Ergothioneine Eye Wash is better than that of the products they used before.

Question 13: Compared with other products you have used to treat dry eye symptoms before, how do you feel about the using effect of experiencing GeneIII L-Ergothioneine Eye Wash? [Single-choice question]

Options	Subtotal	Proportion
Much better than before	24	27.27%
Better than before	51	57.95 %
Same as before	13	14.77%
Not as good as the ones used before	0	0%

The number of people filling in this question effectively: 88

 Publisher:
 Joint Publishers:

 GeneIII Biot convology Co., Lto.
 Pharnex (Shanghai) Information Technology Co., Ltd.

 GeneIII Biot convology Co., Ltd. (sealed)
 Pharnex (Shanghai) Information Technology Co., Ltd. (sealed)

 Appendix 1: Questionnaire on the Experience Feedback of L-Ergo Vice See Eye Warn

All rights reserved by GeneIII Biotech & Pharnex